JP2017521499A5 - - Google Patents

Download PDF

Info

Publication number
JP2017521499A5
JP2017521499A5 JP2017523191A JP2017523191A JP2017521499A5 JP 2017521499 A5 JP2017521499 A5 JP 2017521499A5 JP 2017523191 A JP2017523191 A JP 2017523191A JP 2017523191 A JP2017523191 A JP 2017523191A JP 2017521499 A5 JP2017521499 A5 JP 2017521499A5
Authority
JP
Japan
Prior art keywords
conp
radiation
chemotherapeutic agent
administered
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017523191A
Other languages
English (en)
Japanese (ja)
Other versions
JP6706255B2 (ja
JP2017521499A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/040869 external-priority patent/WO2016011328A1/en
Publication of JP2017521499A publication Critical patent/JP2017521499A/ja
Publication of JP2017521499A5 publication Critical patent/JP2017521499A5/ja
Application granted granted Critical
Publication of JP6706255B2 publication Critical patent/JP6706255B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017523191A 2014-07-17 2015-07-17 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療 Expired - Fee Related JP6706255B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462025861P 2014-07-17 2014-07-17
US62/025,861 2014-07-17
PCT/US2015/040869 WO2016011328A1 (en) 2014-07-17 2015-07-17 Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020086617A Division JP2020158507A (ja) 2014-07-17 2020-05-18 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療

Publications (3)

Publication Number Publication Date
JP2017521499A JP2017521499A (ja) 2017-08-03
JP2017521499A5 true JP2017521499A5 (enExample) 2018-08-23
JP6706255B2 JP6706255B2 (ja) 2020-06-03

Family

ID=55079076

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017523191A Expired - Fee Related JP6706255B2 (ja) 2014-07-17 2015-07-17 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療
JP2020086617A Pending JP2020158507A (ja) 2014-07-17 2020-05-18 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020086617A Pending JP2020158507A (ja) 2014-07-17 2020-05-18 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療

Country Status (9)

Country Link
EP (2) EP3169312B1 (enExample)
JP (2) JP6706255B2 (enExample)
CN (2) CN111184733A (enExample)
AU (1) AU2015289504B2 (enExample)
BR (1) BR112017000800A8 (enExample)
CA (1) CA2955384C (enExample)
MX (1) MX387363B (enExample)
RU (2) RU2019133284A (enExample)
WO (1) WO2016011328A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512761B2 (en) 2009-12-02 2019-12-24 Renovorx, Inc. Methods for delivery of therapeutic materials to treat pancreatic cancer
WO2014197362A1 (en) 2013-06-03 2014-12-11 Ramtin Agah Devices, methods and kits for delivery of therapeutic materials to a pancreas
JP6706255B2 (ja) * 2014-07-17 2020-06-03 バイオキュリティー ファーマシューティカルズ インコーポレイテッド 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療
WO2017174437A1 (en) * 2016-04-05 2017-10-12 Hospital Clínic De Barcelona Ceria nanoparticles for use in the treatment of hepatocellular carcinoma
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
AU2018253189A1 (en) * 2017-04-12 2019-12-05 Vikash J. BHAGWANDIN Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors
EP3615067A1 (en) * 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers
US11052224B2 (en) 2017-05-18 2021-07-06 Renovorx, Inc. Methods for treating cancerous tumors
US10695543B2 (en) 2017-05-18 2020-06-30 Renovorx, Inc. Methods for treating cancerous tumors
US12290564B2 (en) 2017-05-18 2025-05-06 Renovorx, Inc. Methods and apparatuses for treating tumors
WO2019124603A1 (ko) * 2017-12-22 2019-06-27 경상대학교병원 Iwr-1을 유효성분으로 함유하는 켈로이드 예방 또는 치료용 조성물
KR102102535B1 (ko) * 2018-07-26 2020-04-21 서울대학교산학협력단 방사선 보호 나노입자
US20210338718A1 (en) * 2018-09-28 2021-11-04 The Regents Of The University Of Colorado, A Body Corporate Methods for preventing and treating pulmonary inflammation and fibrosis
RU2699670C1 (ru) * 2018-11-16 2019-09-09 Объединенный Институт Ядерных Исследований (Оияи) Способ повышения частоты образования двунитевых разрывов днк в клетках человека при действии ионизирующих излучений в условиях влияния радиомодификаторов
US20230218669A1 (en) * 2020-03-31 2023-07-13 Fred Hutchinson Cancer Center Augmenting antigen-negative cell death in antigen-targeted immunotherapies
US20230157299A1 (en) * 2020-04-30 2023-05-25 University Of Central Florida Research Foundation, Inc. Dispensable nanoparticle based composition for disinfection
WO2023025291A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 冻干制剂溶液及冻干制剂、方法和用途
JP7762796B2 (ja) 2021-08-27 2025-10-30 アセンタウィッツ ファーマシューティカルズ リミテッド Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
EP4509127A4 (en) 2022-04-15 2026-07-15 Ascentawits Pharmaceuticals Ltd CANCER TREATMENT METHOD USING TH-302 ALONE OR IN COMBINATION WITH A PARP INHIBITOR
EP4529926A4 (en) 2022-05-23 2026-07-01 Ascentawits Pharmaceuticals Ltd CANCER TREATMENT METHOD BY COMBINATION OF AN ALKYLATING AGENT PRODRUGATION AND A CELL CYCLE INHIBITOR
CN119894521A (zh) 2022-09-22 2025-04-25 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
EP4674418A1 (en) 2023-02-27 2026-01-07 Ascentawits Pharmaceuticals, Ltd. Solution, freeze-dried formulation, freeze-dried formulation unit package, injection, and injection preparation method
EP4755396A1 (en) 2023-07-28 2026-06-10 Ascentawits Pharmaceuticals, Ltd. Treatment of p53 gene mutation or defect negative cancer and tumor patients
CN121985960A (zh) 2023-10-18 2026-05-05 深圳艾欣达伟医药科技有限公司 治疗p53基因突变阴性、kras基因突变阳性、brca突变阳性患者

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099798A (en) 1997-10-31 2000-08-08 Nanogram Corp. Ultraviolet light block and photocatalytic materials
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
WO2007002662A2 (en) * 2005-06-27 2007-01-04 Edward Via Virginia College Of Osteopathic Medicine Anti-inflammatory, radioprotective, and longevity enhancing capabilities of cerium oxide nanoparticles
JP2011522773A (ja) * 2007-12-27 2011-08-04 インフィニティ ファーマスーティカルズ、インク． 治療剤での癌の処置方法
WO2009132277A1 (en) * 2008-04-25 2009-10-29 The Board Of Regents Of The University Of Oklahoma Inhibition of neovascularization by cerium oxide nanoparticles
US20100015042A1 (en) * 2008-07-03 2010-01-21 Ramot At Tel Aviv University Ltd. Combine radiation therapy and chemotherapy for treating cancer
GB0921596D0 (en) * 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
WO2011109387A1 (en) * 2010-03-01 2011-09-09 Intraop Medical Corporation Radiotherapy combined with hypoxic cell sensitizers
US20120251496A1 (en) * 2011-03-31 2012-10-04 Telik, Inc. Ezatiostat for treating multiple myeloma
CA2869554A1 (en) * 2012-04-04 2013-10-10 Duke University Methods of using cerium oxide nanoparticles to mitigate or protect against radiation injury
DK2861212T3 (en) * 2012-06-13 2017-03-06 Cerion Llc Cerium oxide nanoparticles for the treatment of oxidative stress
EP2928877B1 (en) * 2012-12-06 2020-01-22 Merck Sharp & Dohme Corp. Disulfide masked prodrug compositions and methods
US10463734B2 (en) * 2014-04-25 2019-11-05 The Regents Of The University Of Michigan Nanoparticle therapy in cancer
JP6706255B2 (ja) * 2014-07-17 2020-06-03 バイオキュリティー ファーマシューティカルズ インコーポレイテッド 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療
GB201506381D0 (en) * 2015-04-15 2015-05-27 Isis Innovation Embolization particle

Similar Documents

Publication Publication Date Title
RU2019133284A (ru) Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства
JP2022009090A5 (enExample)
JP2022022264A5 (enExample)
NZ604029A (en) Methods of treating bladder cancer
JP5543956B2 (ja) 癌の処置のための方法および組成物
FI4397376T3 (fi) Yhdistelmä, joka sisältää mek-estäjän ja b-raf-estäjän
JP2014515373A5 (enExample)
JP2013522303A5 (enExample)
AR070047A1 (es) Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
RU2017119230A (ru) Лечение пигментной дистрофии сетчатки n-ацетилцистеинамидом
JP2015528501A5 (enExample)
JP2018526460A5 (enExample)
WO2015032011A1 (zh) 含有亚铁氨基酸螯合物的组合物在制备抗癌症的药物中的用途
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2023522415A5 (enExample)
JP2021169534A5 (enExample)
Tu et al. Localized delivery of nanomedicine and antibodies for combating COVID-19
JP2012525358A5 (enExample)
EP2832356B1 (en) Administration of a therapeutic amount of genistein to mitigate erectile dysfunction resulting from radiation therapy for prostate cancer
JP2016505050A5 (enExample)
JP2011500589A5 (enExample)
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
JP2025517509A5 (enExample)
CN110755432A (zh) 烟酰胺在制备治疗手足皮肤反应制剂中的应用